Angiodynamics (ANGO) Cost of Revenue (2010 - 2026)

Angiodynamics (ANGO) has 17 years of Cost of Revenue data on file, last reported at $36.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 11.46% year-over-year to $36.9 million; the trailing twelve-month figure through Feb 2026 stood at $98.1 million (down 21.01% YoY), and the FY2025 full-year result was $103.1 million, down 30.88% from the prior year.
• Cost of Revenue for Q1 2026 stood at $36.9 million, up from $26.7 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $40.5 million in Q2 2022 and bottomed at $6.3 million in Q2 2025.
• The 5-year median for Cost of Revenue is $32.5 million (2024), against an average of $30.6 million.
• The widest annual swing landed in 2023, when Cost of Revenue surged 96.94%; it then tumbled 80.65% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $40.4 million in 2022, then fell by 3.82% to $38.8 million in 2023, then slipped by 15.13% to $32.9 million in 2024, then fell by 18.91% to $26.7 million in 2025, then surged by 38.31% to $36.9 million in 2026.
• The last three Cost of Revenue figures came in at $36.9 million (Q1 2026), $26.7 million (Q4 2025), and $28.1 million (Q3 2025), per Business Quant data.

Peer Comparison